Reyhaneh Moradi-Marjaneh, Majid Khazaei, Gordon A. Ferns and Seyed H. Aghaee-Bakhtiari* Pages 4611 - 4618 ( 8 )
Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have also recently emerged as important regulators of cancer development and progression. They act by targeting multiple signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding the CRC molecular mechanisms and hence better management of this disease.
SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, Bioinformatics Research Group, Mashhad University of Medical Sciences, Mashhad